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4-3-3 proteins regulate the cell cycle and prevent
apoptosis by controlling the nuclear and cytoplasmic
distribution of signaling molecules with which they
interact. Although the majority of 14-3-3 molecules are
present in the cytoplasm, we show here that in the absence of
bound ligands 14-3-3 homes to the nucleus. We demonstrate
that phosphorylation of one important 14-3-3 binding
molecule, the transcription factor FKHRL1, at the 14-3-3
binding site occurs within the nucleus immediately before
FKHRL1 relocalization to the cytoplasm. We show that the
leucine-rich region within the COOH-terminal 
 
 
 
-helix of
1
 
14-3-3, which had been proposed to function as a nuclear
export signal (NES), instead functions globally in ligand
binding and does not directly mediate nuclear transport.
Efﬁcient nuclear export of FKHRL1 requires both intrinsic
NES sequences within FKHRL1 and phosphorylation/14-3-3
binding. Finally, we present evidence that phosphorylation/
14-3-3 binding may also prevent FKHRL1 nuclear reimport.
These results indicate that 14-3-3 can mediate the relocal-
ization of nuclear ligands by several mechanisms that ensure
complete sequestration of the bound 14-3-3 complex in
the cytoplasm.
 
Introduction
 
14-3-3 proteins are a highly conserved family of molecules
that regulate intracellular signal transduction events within
 
all eukaryotic cells. These 
 
 
 
30 kD 
 
 
 
-helical molecules include
9 proteins in mammals and 2 to 12 proteins in yeast, fungi,
and plants (Fu et al., 2000; Tzivion et al., 2001; van Hemert
et al., 2001). 14-3-3 proteins form homo- and hetero-
dimeric U-shaped structures (Liu et al., 1995; Xiao et al.,
1995) that bind to a large number of phosphorylated signaling
molecules through the large central channel in the center of
the U. For example, 14-3-3 proteins specifically recognize
one or more short phosphoserine/threonine-containing
sequence motifs (Muslin et al., 1996; Yaffe et al., 1997) on
target proteins such as Raf to control mitogen-activated protein
kinase activation, Cdc25 to control G2/M cell cycle progres-
sion,  and BAD and FKHRL1 to control apoptosis. The
molecular details of how 14-3-3 functions in many of these
interactions remains obscure, though it appears that for at
least some of its substrates 14-3-3 participates in regulating
their subcellular localization. Several 14-3-3 binding mole-
cules perform critical functions within the nucleus. These
include the mitotic phosphatase Cdc25 (Peng et al., 1997;
Dalal et al., 1999; Kumagai and Dunphy, 1999; Lopez-Girona
et al., 1999; Yang et al., 1999; Zeng and Piwnica-Worms,
1999; Davezac et al., 2000), the proapoptotic transcription
factor FKHRL1 (Brunet et al., 1999), the yeast transcriptional
activators MSN2 and MSN4 (Beck and Hall, 1999), the
mammalian transcriptional coactivator TAZ and YAP (Ka-
nai et al., 2000), and the histone deacetylases HDAC4, -5,
and -7 (Grozinger and Schreiber, 2000; Wang et al., 2000;
Kao et al., 2001). When complexed to 14-3-3, these molecules
become sequestered in the cytoplasm, impairing their nu-
clear function. Curiously, 14-3-3 proteins are found primary
within the cytoplasm, raising the question of whether phos-
phorylation and 14-3-3 binding occurs in the cytoplasm or
in the nucleus. In addition, there is controversy as to the
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mechanisms through which 14-3-3 causes the relocalization
of these substrates from the nucleus into the cytoplasm.
Insight into the mechanism of 14-3-3–dependent cytoso-
lic sequestration has emerged from a series of studies on the
interaction between 14-3-3 and Cdc25. Initial studies by
Lopez-Girona et al. (1999) identified a leucine-rich se-
quence within the COOH-terminal helix (helix 
 
 
 
I) of 14-
3-3 that was highly homologous to known nuclear export
signals (NESs).* These authors proposed that 14-3-3 func-
tioned essentially as an “attachable NES” to transport nu-
clear Cdc25 to the cytoplasmic compartment by a piggy-
back mechanism. This view was contradicted by detailed
studies by both Kumagai and Dunphy (1999) and Zeng and
Piwnica-Worms (1999). These authors showed that point
mutations in this leucine-rich sequence of 14-3-3 prevented
Cdc25 from being sequestered in the cytoplasm by disrupt-
ing its binding to 14-3-3. Furthermore, our x-ray crystal-
lographic studies of 14-3-3–peptide complexes of two ca-
nonical 14-3-3 binding motifs R[S/Ar]XpSXP and RX[Ar/
S]XpSXP, (pS denotes phosphoserine and Ar denotes aro-
matic residues) showed that the critical leucine and isoleu-
cine residues within helix 
 
 
 
I were directly involved in bind-
ing to the phosphopeptide (Rittinger et al., 1999). Taken
together, these studies raise the possibility that the primary
function of helix 
 
 
 
I may be to mediate interactions between
14-3-3 and many phosphoprotein ligands but do not prove
that this sequence cannot function as an NES.
The current prevailing mechanism for how 14-3-3 pro-
teins mediate changes in the subcellular localization of
Cdc25 comes from elegant studies by Kumagai and Dunphy
(1999) and Yang et al. (1999). Cdc25 was found to be ex-
ported from the nucleus at a constant rate. This process in-
volved intrinsic NES sequences in Cdc25 but was not modi-
fied by phosphorylation/14-3-3 binding. In contrast, 14-3-
3–bound Cdc25 within the cytoplasm showed a decreased
rate of nuclear import as a result of masking a Cdc25 nuclear
localization signal (NLS) sequence, thereby inhibiting the
interaction of Cdc25 with importin-
 
 
 
. Whether this mecha-
nism operates for all 14-3-3–bound ligands or whether a
subset of ligands can undergo an increase in nuclear export
upon phosphorylation/14-3-3 binding is not known.
In the present study, we sought to clarify where 14-3-3
binding to its ligands occurred, determine whether the leu-
cine-rich helix 
 
 
 
I truly functions as an NES, and identify
features of both 14-3-3 and one of its nuclear ligands, the
transcription factor FKHRL1, that are critical for the move-
ment of this nuclear ligand to the cytoplasm. Surprisingly,
we find that in the absence of bound ligands the majority of
14-3-3 is localized to the nucleus, where a large number of
14-3-3 ligands are present. For FKHRL1, growth-factor
stimulation, which activates AKT, first leads to the phos-
phorylation of FKHRL1 at its 14-3-3 binding site within
the nucleus immediately before FKHRL1 nuclear export.
Helix 
 
 
 
I of 14-3-3 does not function as an attachable NES
but is involved in a general manner in the binding of
phosphorylated ligands. Instead, rapid nuclear export of
FKHRL1 requires both NES sequences that are intrinsic to
FKHRL1 and phosphorylation/14-3-3 binding. Once in the
cytoplasm, FKHRL1 remains phosphorylated and bound to
14-3-3, thereby preventing nuclear reimport. Together with
the studies on Cdc25 cited above, our study suggests that
14-3-3 can function through multiple mechanisms that may
cooperate to ensure complete sequestration of the phosphor-
ylated 14-3-3 ligand in the cytoplasm.
 
Results
 
Different intracellular localization of 14-3-3 
and its ligands
 
To investigate the normal intracellular distribution of 14-
3-3 proteins and their ligands, U2OS cells were immu-
nostained with a polyclonal antibody that recognizes all 14-
3-3 isotypes (pan 
 
 
 
–14-3-3) or with a monoclonal antibody
generated against the 14-3-3
 
 
 
 isotype (Fig. 1 A). Identical
immunostaining results were obtained with both antibodies,
though the performance of the monoclonal anti–14-3-3
 
 
 
*Abbreviations used in this paper: IGF, insulin-like growth factor; LMB,
leptomycin B; NES, nuclear export signal; NLS, nuclear localization sig-
nal; WT, wild-type.
Figure 1. Different subcellular distributions of 14-3-3 
and its ligands. (A) U2OS cells immunostained for 
14-3-3  (left) and corresponding DAPI staining (right). 
Bar, 10  m. (B) Biochemical fractionation of U2OS 
cells followed by immunoblotting using an antibody 
recognizing all 14-3-3 isotypes (N, nuclear fraction; 
C, cytoplasmic fraction). Blots were probed with 
anti– -tubulin (cytoplasmic) or anti–lamin B 
(nuclear) as controls. A very small amount of 14-3-3 is 
present in the nuclear fraction but cannot be seen in this 
exposure. (C) U2OS cells were metabolically labeled 
with [
35S]methionine, fractionated, and nuclear (N) and 
cytoplasmic (C) fractions containing equal amounts of 
protein and radioactivity were incubated with beads 
containing GST–14-3-3 or GST alone. Bound proteins 
were visualized by SDS-PAGE and autoradiography. A 
small portion of the input sample is shown on the left 
(Lysate lanes). Positions of molecular weight markers, in 
kD, are indicated. The prominent band at  28 kD in the 
cytoplasmic/14-3-3–GST lane (arrow) is endogenous 
U2OS 14-3-3 (Rittinger et al., 1999). 
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antibody was superior, and this antibody was therefore used
preferentially. Both antibodies showed that the vast majority
of 14-3-3 had a diffuse cytoplasmic and perinuclear distribu-
tion in unsychronized cells, consistent with findings re-
ported by others (Hermeking et al., 1997; Kumagai and
Dunphy, 1999; Lopez-Girona et al., 1999; Grozinger and
Schreiber, 2000). A similar cytoplasmic distribution of 14-
3-3 was observed after biochemical separation of the cells
into cytoplasmic and nuclear fractions followed by immuno-
blotting with the pan 
 
 
 
–14-3-3 antibody (Fig. 1 B). To in-
vestigate the intracellular localization of all ligands capable
of 14-3-3 binding, cells were metabolically labeled with
[
 
35
 
S]methionine, subjected to nuclear and cytoplasmic frac-
tionation, and incubated with 14-3-3–GST fusion proteins
in pull-down assays. Surprisingly, these experiments revealed
that many 14-3-3 binding ligands were in the nuclear frac-
tion (Fig. 1 C) despite the predominantly cytoplasmic loca-
tion of endogenous 14-3-3.
 
14-3-3 normally transits into and out of the nucleus
 
The findings in Fig. 1 suggest that free 14-3-3 might dy-
namically transit into the nucleus to bind ligands followed
by export of the ligand-bound 14-3-3 complex out of the
nucleus. To investigate if 14-3-3 was actively exported out
of the nucleus, U2OS cells were incubated with leptomycin
B (LMB), a specific inhibitor of Crm1- and NES-dependent
nuclear export (Fornerod et al., 1997; Fukuda et al., 1997;
Ossareh-Nazari et al., 1997), and the distribution of 14-3-3
was analyzed by immunofluorescence. As shown in Fig. 2, A
and B, incubation of U2OS cells with LMB caused the pro-
gressive accumulation of endogenous 14-3-3 in the nucleus,
causing a 2.5-fold increase in nuclear 14-3-3 staining within
1.5 h and a nearly 15-fold increase in nuclear 14-3-3 accu-
mulation by 18 h with the majority of 14-3-3 being clearly
localized within the nuclear compartment (Fig. 2). These ex-
periments demonstrate that nuclear export of 14-3-3 is an
NES/Crm1-dependent process but do not reveal whether
the NES is present on 14-3-3 or on the bound ligand.
 
The leucine-rich sequence in 14-3-3 functions in ligand 
binding rather than nuclear export
 
14-3-3 proteins contain a leucine-rich sequence in helix 
 
 
 
I
that matches the consensus sequence for nuclear export, and
Lopez-Girona et al. (1999) have argued that this sequence
functions as an “attachable NES” for 14-3-3–dependent nu-
clear export of Cdc25. However, several lines of evidence
suggest that this leucine-rich sequence in helix 
 
 
 
I functions
primarily in binding to phosphorylated ligands, includ-
ing crystallographic studies of two 14-3-3–phosphopeptide
complexes (Yaffe et al., 1997; Rittinger et al., 1999) and
mutation and deletion studies involving interactions be-
tween this region of 14-3-3 with two specific phosphory-
lated ligands, Cdc25C (Kumagai and Dunphy, 1999; Zeng
and Piwnica-Worms, 1999) and Raf (Thorson et al., 1998).
To determine if helix 
 
 
 
I of 14-3-3 has a very general func-
tion in binding to many serine-phosphorylated 14-3-3 bind-
ing proteins, we used commercial antibodies that had been
generated against one of the major 14-3-3 phosphoserine
binding motifs. This motif is present in many 14-3-3
ligands (Muslin et al., 1996; Yaffe et al., 1997), and this an-
tibody detects a large number of immunoreactive bands in
293T total cell lysates (Fig. 3 A, TCL lane), which are spe-
cifically pulled down by wild-type (WT) 14-3-3–GST (14-
3-3
 
 
 
 WT lane) but not by a 14-3-3–GST point mutant that
is unable to bind to ligands (14-3-3
 
 
 
 MT lane, discussed in
more detail below). Deletion of residues 215–255 in 14-3-
3
 
 
 
, which includes both helix 
 
 
 
I and the extreme COOH-
terminal tail (Fig. 3 A, 
 
 
 
C lanes, and Fig. 4 A), completely
abrogated binding of 14-3-3 to all of the detected proteins.
The extreme COOH-terminal tail of 14-3-3 (residues 233–
255 in 
 
 
 
) cannot be visualized in 14-3-3 x-ray structures
(Liu et al., 1995; Xiao et al., 1995) (Fig. 4 A), and its contri-
bution to ligand binding is unknown. Removal of this re-
gion while maintaining helix 
 
 
 
I reduced but did not elimi-
nate 14-3-3 binding (Fig. 3 A, 
 
 
 
T lanes), demonstrating
that helix 
 
 
 
I plays an essential role in binding to many phos-
phorylated protein ligands.
To specifically address the role of the leucine and isoleu-
cine residues within helix 
 
 
 
I, we progressively mutated these
Figure 2. LMB sequesters endogenous 14-3-3 in the nucleus. (A) 
Immunostaining of U2OS cells for endogenous 14-3-3  with (right) 
or without (left) treatment with LMB for 18 h. Corresponding DAPI 
staining is shown on the bottom. Bar, 10  m. (B) Quantitative analysis 
of 14-3-3  location. Subcellular localization of 14-3-3  was scored 
according to whether it was higher in the nucleus (N   C), evenly 
distributed between nucleus and cytoplasm (C   N), or higher in 
cytoplasm (C   N) for 300 cells at each time point. Results are the 
mean   SD from three separate experiments. 
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residues to alanines in a systematic manner and determined
if the 14-3-3 mutants could bind to ligands (Fig. 3, B and
C). Mutation of a single leucine, Leu-216, resulted in an
 
 
 
50% global reduction in ligand binding (Fig. 3 B, LA
 
1
 
lane). A double Ala substitution for Leu-216/Ile-217 (LA
 
2
 
lane) or a triple Ala substitution for Leu-216/Ile-217/Leu-
220 (LA
 
3
 
 lane) further reduced ligand binding to 
 
 
 
5% or
less of that seen with WT 14-3-3. Additional Ala substitu-
tions of Leu-221 (LA
 
4
 
 lane), Leu-225 (LA
 
5
 
 lane), and Leu-
227 (LA
 
6
 
 lane) eliminated binding altogether. Thus, the ma-
jor role of the leucine and isoleucine residues within helix 
 
 
 
I
appears to be binding phosphoproteins.
 
A 14-3-3 mutant, which cannot bind to ligands, 
accumulates in the nucleus
 
The experiments described above strongly argue that helix
 
 
 
I functions primarily in ligand binding but cannot com-
pletely exclude the possibility that helix 
 
 
 
I might also some-
how mediate nuclear export. To directly address whether he-
lix 
 
 
 
I can function as an NES in vivo, we took advantage of
a 14-3-3 point mutant in which Lys-49 is replaced by Glu
(K49E) in the presence of an intact WT helix 
 
 
 
I. This mu-
tant, developed by Fu and colleagues, has the same con-
formation as WT 14-3-3 and is able to form homo- and
heterodimers in vitro and in vivo (Zhang et al., 1997; un-
published data) but is unable to bind to Raf (Zhang et al.,
1997). X-ray crystallographic studies revealed that Lys-49
forms part of a positively charged substrate-binding pocket
in the central binding groove of 14-3-3 (Fig. 4 A), where it
directly coordinates the phosphoserine phosphate of 14-3-3
binding peptides (Yaffe et al., 1997; Petosa et al., 1998; Rit-
tinger et al., 1999). These structural observations on pep-
tides suggested that the K49E mutation would be generally
deficient in binding to phosphorylated protein ligands,
while preserving its leucine-rich NES-like sequence. Indeed,
the 14-3-3
 
 
 
 K49E mutant is unable to bind to numerous
14-3-3 binding proteins in cell extracts (Fig. 3 A, MT lanes),
allowing the intrinsic function of the leucine-rich sequence
in helix 
 
 
 
I to be directly investigated without complexities
arising from 14-3-3 ligand interactions.
If the leucine-rich sequence in helix 
 
 
 
I functions as a true
NES for 14-3-3, then the unliganded 14-3-3
 
 
 
 K49E protein
should localize exclusively in the cytoplasm. Stable U2OS
cell lines expressing either WT or K49E mutant Xpress-
tagged 14-3-3
 
 
 
 proteins were generated, and three different
stable cell lines for each construct were studied in detail (Fig.
Figure 3. The Leu-rich sequence in helix 
 I of 14-3-3 is responsible for ligand 
binding. (A) In the context of the entire 
14-3-3 molecule, the Leu-rich helix  I 
functions primarily in ligand binding. 
Total cell lysates from 293T cells were 
incubated with beads containing the 
indicated GST–14-3-3 constructs or GST 
alone and bound proteins analyzed by 
SDS-PAGE and immunoblotting using an 
antibody against the 14-3-3 phospho-
serine-binding epitope. TCL, total cell 
lysate; WT, WT 14-3-3; MT, K49E mu-
tant;  C, GST–14-3-3 (1–214);  T, 
GST–14-3-3 (1–232). The mobility of 
molecular mass standards in kD is 
indicated. (B and C) Direct contribution 
of leucine and isoleucine residues in 
helix  I to ligand binding. 293T cell 
lysates as in A were incubated with 
beads containing immobilized WT 
GST–14-3-3  or GST–14-3-3  containing 
sequential Ala substitutions for Leu/Ile 
residues in helix  I. Bound proteins 
were analyzed by SDS-PAGE followed 
by immunoblotting using the antibody 
against the 14-3-3 phosphoserine-binding 
epitope (top) or stained with Coomassie 
blue to quantitate the amount of bead-
bound GST–14-3-3 protein and GST 
alone (bottom, arrows). The bottom 
part of C shows the contributions from 
each Leu/Ile residue to phosphopeptide 
binding based on the x-ray structure of 
a 14-3-3–phosphopeptide complex 
(Rittinger et al., 1999). 
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4, B–D). The ligand-binding defective 14-3-3
 
 
 
 K49E mu-
tant was found predominantly in the nucleus in 100% of the
stable transfected cells in all cell lines investigated (Fig. 4 D,
left). In contrast, the tagged WT 14-3-3 protein was found
almost exclusively in the cytoplasm (Fig. 4 D, right), show-
ing the identical staining pattern as that seen with endoge-
nous 14-3-3 (Fig. 1 A). Expression levels of tagged WT 14-
3-3
 
 
 
 in all three cell lines were 
 
 
 
3.5- to 5-fold lower than
those seen with the K49E mutant (Fig. 4, B and C), perhaps
due to deleterious effects of 14-3-3 on cell growth (Herme-
king et al., 1997; Kumagai et al., 1998). However, in all cases
the expression levels of the stably transfected 14-3-3 proteins
were less than or equal to those of endogenous 14-3-3 (Fig.
4 C). The possibility that localization of the K49E mutant
compared with WT was due to differences in expression lev-
els was ruled out by transient transfection experiments. Un-
der these conditions, both WT and mutant proteins are ex-
pressed at equivalent levels (albeit at significantly higher
concentrations than the endogenous 14-3-3 proteins) and
resulted in the same nuclear localization for the K49E mu-
tant (unpublished data). Together, these findings show con-
clusively that the leucine-rich sequence within 14-3-3 does
not function as an NES in the absence of bound ligands.
The nuclear localization of the K49E 14-3-3 mutant
strongly argues that nuclear export of 14-3-3 requires ligand
binding. In addition, the LMB experiments indicate that the
14-3-3 is exported in an NES-dependent manner. There-
fore, we hypothesized that it is NES sequences on the bound
ligand which drive the export of 14-3-3–ligand complexes
out of the nucleus and that this process is facilitated by 14-
3-3 binding. To directly investigate the contribution of the
14-3-3–bound cargo to nuclear export, we focused the re-
mainder of this study on one particular 14-3-3 binding
ligand, the human Forkhead transcription factor FKHRL1
(Brunet et al., 1999).
 
The export of the 14-3-3 ligand FKHRL1 
requires Crm1, intrinsic FKHLR1 NES sequences,
and 14-3-3 binding
 
The subcellular localization of FKHRL1 is dependent on its
phosphorylation by the protein kinase Akt. In the absence of
growth factor, Akt is inactive and FKHRL1 is present in the
nucleus in an unphosphorylated form. Upon growth fac-
tor stimulation, Akt is activated, directly phosphorylating
FKHRL1 at T32 and S253, and to a lesser extent at S315,
and resulting in FKHRL1 relocalization from the nucleus to
the cytoplasm (Brunet et al., 1999). Similar AKT-dependent
changes in subcellular localization have also been observed
for the additional FKHRL1 human homologs AFX and
FKHR (Brownawell et al., 2001; Rena et al., 2001) and for
the 
 
Caenorhabditis elegans
 
 homologue 
 
daf-16
 
 (Cahill et al.,
2001). Phosphorylation at T32 and S253 causes FKHRL1
to bind to 14-3-3, suggesting that the interaction between
FKHRL1 and 14-3-3 may play an important role in regulat-
ing the subcellular localization of the complex. COOH-ter-
minal to the two 14-3-3 binding sites, FKHRL1 contains
two sequences that closely match a consensus for NES se-
quences (Fig. 5 A), suggesting that nuclear export of 14-3-
3–FKHRL1 complexes might involve a cooperative process
involving both the FKHRL1 NES and 14-3-3 binding.
To first determine if FKHRL1 nuclear export is a Crm1-
and NES-dependent process, we followed FKHLR1 subcel-
lular localization in fibroblasts in the presence or absence of
LMB upon stimulation by growth factors (Fig. 5 B). We
Figure 4. A mutant 14-3-3, which 
cannot bind to ligands, accumulates 
in the nucleus. (A) Structural cartoon of 
the 14-3-3 dimer. Monomers (red and 
green) consists of nine  -helices. Helix 
 I containing the leucine-rich sequence 
is purple with leucine and isoleucine 
residues shown in ball and stick. Lys-49 
in the phosphoserine-binding pocket is 
indicated. Only three residues in the 
extreme COOH-terminal tail (cyan) are 
visible in the x-ray structures. The figure 
was generated with Molscript and 
Raster3D. (B) Expression of Xpress-tagged 
14-3-3 WT and K49E mutant protein in 
different stable U2OS cell lines. Total 
cell lysates corresponding to equivalent 
amounts of total protein from stable cell 
lines expressing empty vector (lane 1), 
WT 14-3-3 (lanes 2–4), or K49E mutant 
(lanes 5–7) were analyzed by SDS-PAGE 
and immunoblotting using an anti-
Xpress epitope antibody. (C) Comparison 
of Xpress-tagged and endogenous 14-3-3 
levels in several U2OS stable cell lines. 
Total cell lysates from stable cell lines 
containing empty vector (lane 1), WT 14-3-3  (clone #15) (lane 2) and 14-3-3  K49E mutant (clone #21) (lane 3) were immunoblotted using 
a pan anti–14-3-3 antibody. Arrowhead indicates endogenous 14-3-3 in U2OS cells; arrow indicates Xpress-tagged 14-3-3. (D) Immunostaining 
of stable U2OS cell lines expressing WT 14-3-3  (clone #15, left) or 14-3-3  K49E mutant (clone #21, right) with the anti-Xpress antibody. 
Corresponding DAPI staining was shown in the middle, and the merged image is shown on the bottom. Bar, 10  m. Each of three stable cell 
lines showed identical results. 
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found that treatment of cells with LMB prevented the relo-
calization of FKHRL1 from the nucleus to the cytoplasm in
response to serum or insulin-like growth factor (IGF)-I, in-
dicating that FKHRL1 was exported from the nucleus in an
NES-dependent manner.
To investigate whether the intrinsic FKHRL1 NES se-
quences were responsible for the NES-dependent FKHRL1
nuclear export, we generated mutants of FKHRL1 in which
the critical leucine or methionine residues in NES1 or NES2
were replaced by alanines either individually or in combina-
tion (Fig. 5, C and D). We found that an FKHRL1 mutant
in which both NES1 and -2 were mutated remains localized
in the nucleus even in the presence of growth factors, indi-
cating that the NES sequences of FKHRL1 are required for
the nuclear export of this protein. Importantly, we verified
that the FKHRL1 NES mutant protein, which localizes to
the nucleus, still binds to 14-3-3 (Fig. 5 E). This indicates
that in the absence of a functional NES in FKHRL1, 14-3-3
binding alone is not sufficient to promote the efficient local-
ization of FKHRL1 from the nucleus to the cytoplasm.
Consistent with our previous results, we found that a tri-
ple point mutant of FKHRL1, which does not bind to 14-
3-3 (Fig. 5 E) because the key 14-3-3 binding residues T32
and S253 has been mutated to alanine, remains localized
within the nucleus even in the presence of growth factors
(Fig. 5, C and D). As this FKHRL1 mutant contains the in-
tact NESs, this result further indicates that the NESs of
FKHRL1 are not sufficient to lead to the net export of
FKHRL1 out of the nucleus in the absence of 14-3-3 bind-
ing. Therefore, both the NES of FKHRL1 and FKHRL1’s
ability to bind 14-3-3 appear to be necessary to promote ef-
ficient FKHRL1 nuclear export. In addition, we found in
transient transfection studies that FKHRL1 bound to Crm1
in a manner that is dependent on FKHRL1 NESs, further
confirming that the NES sequences of FKHRL1 play a role
in a Crm1-dependent nuclear export of this transcription
factor (unpublished data). However, in these overexpression
studies we have been unable to show that the interaction be-
tween FKHRL1 and Crm1 is facilitated by 14-3-3. Never-
theless, 14-3-3 may enhance the binding of FKHRL1 to
Crm1 in a context where both proteins are expressed at
physiological levels, or alternatively 14-3-3 may enhance the
export of FKHRL1 without directly enhancing its binding
to Crm1.
 
FKHLR1 undergoes phosphorylation within the nucleus 
upon growth factor stimulation before nuclear 
export—roles of intrinsic NES and NLS sequences and 
the 14-3-3 binding site in FKHRL1 localization
 
The experiments described above reflect the overall subcellular
distribution of FKHRL1 at a given time but do not address
Figure 5. Both FKHRL1 nuclear export 
sequences and interaction with 14-3-3 
are necessary for efficient nucleocyto-
plasmic transport. (A) Schematic 
illustration of FKHRL1 showing the 
T32, S253, and S315 phosphorylation 
sites and the 14-3-3 binding sites. The 
two NES sequences in FKHRL1 are 
shown (NES1, amino acids 369–378; 
NES2, amino acids 386–396). (B) LMB 
treatment prevents FKHRL1 nuclear 
export even in the presence of growth 
factors. CCL39 cells were transfected 
with a WT HA-FKHRL1 construct. Cells 
were starved for 20 h, incubated with 
LMB for 2 h, and then stimulated with 
10% serum (FCS) or 100 ng/ml IGF-I for 
15 min. Localization of FKHRL1 WT or 
mutants was monitored by immunolocal-
ization with the anti-HA antibody. 
Quantitative analysis of a representative 
experiment is shown. C, cytoplasm; 
C   N, cytoplasm and nucleus; N, 
nucleus. (C) Mutation of FKHRL1 NES 
or 14-3-3 binding site prevents FKHRL1 
relocalization from the nucleus to the 
cytoplasm in the presence of growth 
factors. CCL39 cells were transfected 
with a WT HA-FKHRL1 construct or a 
mutant of both NES mutant of FKHRL1 
(NESm) or a mutant in which all three phosphorylation sites of FKHRL1 have been replaced by alanine (TM). Cells were incubated in the 
presence of 10% serum (FCS). Localization of FKHRL1 WT or mutants was monitored by immunolocalization with the anti-HA antibody. (D) 
Quantitative analysis of FKHRL1 localization. Results are the mean   SD from three separate experiments. C, cytoplasm; C   N, cytoplasm 
and nucleus; N, nucleus. (E) Mutation of FKHRL1 NES does not abolish binding to 14-3-3, whereas mutation of the phosphorylation sites of 
FKHRL1 does. 293T cells were cotransfected with a construct encoding M2–14-3-3  and either empty vector (CTL) or vectors encoding HA-FKHRL1 
WT, T32A/S253A/S315A (TM), or a mutant of the putative NES1 and 2 (NESm). 14-3-3 was immunoprecipitated with the anti-M2 antibody, 
and the immune complex was analyzed by SDS-PAGE and immunoblotted with the anti-HA antibody (top). Total cell lysates (TCL) were also 
analyzed by direct immunoblotting with the anti-HA antibody (middle) or the anti-M2 antibody (bottom).14-3-3 and FKHRL1 nucleocytoplasmic transport | Brunet et al. 823
the dynamic sequence of events involving FKHRL1 relocal-
ization from the nucleus to the cytoplasm. Based on the re-
sults from Figs. 1–4, we hypothesized that 14-3-3 binding to
FKHRL1 might occur in the nucleus, exposing the FKHRL1
NES and facilitating export of the 14-3-3–FKHRL1 complex
to the cytoplasm. Once in the cytoplasm, 14-3-3 may have
additional function in masking potential NLS, thereby pre-
venting reentry of the ligands into the nucleus.
This sequence of events would require the phosphoryla-
tion of FKHRL1 in the nucleus to precede its cytoplasmic
translocation. To investigate this, WT HA-tagged FKHRL1
was expressed in CCL39 fibroblasts, and the kinetics of
phosphorylation and FKHRL1 relocalization were exam-
ined using immunofluorescence experiments with an anti-
body to HA and an antibody specific to phospho-Thr32
(Fig. 6, WT panels). When cells were deprived of survival
factors, WT FKHRL1 was localized in the nucleus and was
not phosphorylated at Thr32. At short times after stimula-
tion by IGF-1 phosphorylation of WT FKHRL1 at the 14-
3-3 consensus binding site, Thr32 was detected, whereas
FKHRL1 remained in the nucleus (Fig. 6, WT, 2 min).
Upon longer stimulation times, the phosphorylated form of
FKHRL1 began to appear predominantly in the cytoplasm
(Fig. 6, WT, 5 and 15 min). In contrast, the NES1/2 mu-
tant (NESm) was efficiently phosphorylated by IGF-1
within the nucleus, but unlike WT FKHRL1 the FKHRL1
NESm remained within the nucleus even after relatively
long incubation times (Fig. 6, NESm 2, 5, and 15 min pan-
els). Thus, phosphorylation of FKHRL1 at Thr32, which
generates a 14-3-3 binding site, occurs within the nucleus
before FKHRL1 cytoplasmic relocalization. The finding
that phosphorylation of FKHRL1 to generate 14-3-3 bind-
ing sites occurs within the nucleus together with the nuclear
localization of ligand-free 14-3-3 proteins further suggests
that 14-3-3 binding to nuclear FKHRL1 may facilitate its
NES-dependent export.
It is possible that 14-3-3 binding to FKHRL1 may also
function in the cytoplasm to prevent FKHRL1 reentry into
the nucleus, perhaps by masking NLS. Two regions in the
primary sequence of FKHRL1 represent putative NLS se-
quences in the vicinity of the second phosphorylation site
(Ser 253). To determine whether these regions indeed
played a role in the subcellular localization of FKHRL1, we
mutated the arginines 248, 249, and 250 into alanines
(RRR → AAA) and the lysines 269, 270, and 271 to ala-
nines (KKK → AAA). Expression of these FKHRL1 mu-
tants within cells followed by immunofluorescence experi-
ments revealed that the RRR → AAA mutant of FKHRL1
no longer localized in the nucleus, even in the absence of
survival factors (Fig. 7, A and B,   lanes) or after complete
inhibition of AKT using the phosphatidylinositol 3-kinase
inhibitor LY294002 (Fig. 7, A and B, LY lanes). The KKK
→ AAA mutant of FKHRL1 also showed less nuclear local-
ization in the absence of survival factors compared with WT
FKHRL1 (Fig. 7 B) but did accumulate in the nucleus when
the basal activity of Akt in serum-starved cells was com-
pletely eliminated by LY294002 (Fig. 7, A and B). Thus, the
RRR sequence plays a major role, whereas the KKK region
plays a minor role, in the nuclear localization of FKHRL1.
These results indicate that the region surrounding the sec-
ond 14-3-3 phosphorylation site is an NLS and further sug-
gests that phosphorylation of this site, either by introducing
negatively charged residue or by masking due to 14-3-3
binding, may participate in the retention of FKHRL1 in the
cytoplasm. These results are in excellent agreement with
the role of similar RRR and KKK sequences in AFX
(Brownawell et al., 2001) and an RRR sequence in FKHR
(Rena et al., 2001).
To experimentally determine the relative contributions
of the NES, NLS, and 14-3-3 in promoting the export
and/or preventing the reimport of FKHRL1, we analyzed
the kinetics of cytoplasmic relocalization of a series of
Figure 6. Phosphorylation of FKHRL1 at the 14-3-3 
binding site occurs within the nucleus immediately 
before nuclear export. CCL39 fibroblasts were trans-
fected with WT HA-tagged FKHRL1 or a mutant of 
NES1 and -2 (NESm). Cells were serum starved for
12 h and incubated in the presence of 20  M 
LY294002 for the last hour and then incubated in the 
presence of 100 ng/ml IGF-I for the indicated periods 
of time. Cells were rapidly fixed with paraformalde-
hyde, and FKHRL1 was detected by immunolocaliza-
tion with an anti-HA antibody. Phosphorylation of 
FKHRL1 was assessed by immunolocalization with an 
antibody to phospho-Thr32. Representative pictures 
are shown. NESm, mutant of NES1 and NES2 of 
FKHRL1.824 The Journal of Cell Biology | Volume 156, Number 5, 2002
FKHRL1 mutants (Fig. 8). Cells were first treated with the
phosphatidylinositol 3-kinase inhibitor LY294002 to drive
localization of all FKHRL1 mutants into the nucleus.
LY294002 was then washed out, and cells were stimulated
by IGF-I for short periods of time. FKHRL1 subcellular
localization was determined by immunolocalization, and
the number of cells in which FKHRL1 is present in the cy-
toplasm was quantified. We found that WT FKHRL1 was
exported rapidly to the cytoplasm, and the percentage of
cells showing exclusively cytoplasmic FKHRL1 remained
constant at  40% (Fig. 8, WT) with the remaining 60%
of cells displaying both cytoplasmic and nuclear localiza-
tion. In contrast, the NES mutant of FKHRL1 did not re-
localize to the cytoplasm even after longer stimulation with
IGF-I. Next, we tested the cytoplasmic relocalization of the
FKHRL1 RRR → AAA NLS mutant. We found that this
NLS mutant was also exported from the nucleus with simi-
lar kinetics at early times to those of WT FKHRL1 (Fig. 8,
RRR). However, after longer times a larger number of cells
containing this mutant displayed exclusively cytoplasmic
FKHRL1 staining, suggesting that the NLS of FKHRL1
plays a role after longer times of stimulation to promote
the reentry of WT FKHRL1 into the nucleus. Phosphory-
lation of Ser253 could interfere with the basic residues of
the NLS or 14-3-3 binding may mask this stretch of basic
residues, thereby preventing FKHRL1 from being reim-
ported to the nucleus at longer time of stimulation by
growth factors.
To specifically address the role of 14-3-3 binding in the
export of FKHRL1 from the nucleus, we next tested the ex-
port kinetics of FKHRL1 mutants in which the canonical
14-3-3 binding site at T32 or both 14-3-3 binding sites at
T32 and S253 were replaced by alanines (Fig. 8, T32A and
T32A/S253A). These experiments conclusively show that
neither T32A nor T32A/S253A are exported efficiently
from the nucleus even at short times of stimulation by
growth factors. These results indicate that 14-3-3 binding to
FKHRL1 is critical for the early nuclear events leading to ex-
port of FKHRL1 to the cytoplasm in a manner that requires
FKHRL1 NES.
Together, these findings suggest that 14-3-3 binding to
ligands can occur within the nucleus and may facilitate the
nuclear export of the 14-3-3–ligand complex through the
NES of the bound ligand. In the cytoplasm, 14-3-3 may
have an additional role in preventing the reimport of ligands
such as FKHRL1.
Discussion
In this study, we have shown that (a) although 14-3-3 pro-
teins are predominantly localized in the cytoplasm, a large
number of ligands are localized within the nucleus; (b) en-
dogenous 14-3-3, fully competent to bind ligands, can be
trapped in the nucleus by inhibiting Crm1-dependent nu-
clear export with LMB; (c) the leucine-rich putative NES se-
quence in 14-3-3, despite its structural homology to known
Figure 7. Role of NLS and NES sequences in FKHRL1 subcellular localization. (A) CCL39 fibroblasts were transfected with a WT HA-tagged 
FKHRL1 construct or with FKHRL1 mutant constructs. Cells were either incubated in the presence of 10% serum (FCS) or 100 ng/ml IGF-I 
(IGF-I), or serum-starved for 12 h ( ), or incubated in the presence of 20  M LY294002 for 1 h (LY). FKHRL1 was detected by immunolocalization 
with an anti-HA antibody. RRR, RRR → AAA mutant of FKHRL1; KKK, KKK → AAA mutant of FKHRL1; NESm, mutant of NES1 and NES2 of 
FKHRL1; TM, triple mutant of FKHRL1 (T32A/S253A/S315A). (B) Quantification of a representative experiment is shown.14-3-3 and FKHRL1 nucleocytoplasmic transport | Brunet et al. 825
NES sequences (Rittinger et al., 1999) and its ability to
function as an NES in isolation when fused to GFP (unpub-
lished data), functions primarily in phosphoprotein binding
and not as an NES in the context of the intact 14-3-3 mole-
cule; (d) a mutant 14-3-3, which cannot bind to ligands,
homes to the nucleus; (e) the nuclear 14-3-3 ligand
FKHRL1 is phosphorylated at its major 14-3-3 binding site
within the nucleus before its export into the cytoplasm; and
(f) at least for FKHRL1, rapid export from the nucleus to
the cytoplasm requires both phosphorylation/14-3-3 bind-
ing and NES sequences within the bound ligand. In addi-
tion, we have identified NLS sequences within FKHRL1
that are responsible for its nuclear localization in the absence
of phosphorylation. These data suggest that for nuclear
FKHRL1, the sequence of events after growth factor stimu-
lation involves phosphorylation at the 14-3-3 binding site
within the nucleus, where ligand-free 14-3-3 molecules are
located, followed by rapid nuclear export that requires both
phosphorylation/14-3-3 binding and intrinsic NES se-
quences in FKHRL1. Once FKHRL1 has been exported to
the cytoplasm, phosphorylation/14-3-3 binding may play an
additional role in preventing nuclear reimport possibly by
masking the FKHRL1 NLS.
Our observation that many potential 14-3-3 binding sub-
strates are present in the nuclear fraction and that FKHRL1
is phosphorylated at its major 14-3-3 binding site within the
nucleus suggests that kinases, such as AKT, Chk1, and
Chk2, may act preferentially within this compartment, con-
ferring 14-3-3 binding to some of their substrates. Further-
more, the observations that LMB treatment led to accumu-
lation of endogenous 14-3-3 in the nucleus and that a K49E
mutant of 14-3-3, which does not bind to ligands, localizes
preferentially within the nucleus suggests that unliganded
14-3-3 normally transits to the nuclear compartment where
binding to some ligands can occur. It would also be interest-
ing to investigate the rate of import of 14-3-3 into the nu-
cleus to address whether dissociation of ligands from pre-
formed cytoplasmic complexes determines the rate of 14-3-3
nuclear import. We found that elimination or mutation of
the leucine-rich sequence within helix  I disrupts binding to
numerous phosphorylated protein ligands. This is in excel-
lent agreement with the results of more focused mutational
studies reported by others examining 14-3-3 binding to Raf
and Cdc25 (Thorson et al., 1998; Wang et al., 1998; Kuma-
gai and Dunphy, 1999; Zeng and Piwnica-Worms, 1999).
Thus, the primary and general function of this  -helix is to
directly participate in ligand binding. Furthermore, the ob-
servation that this leucine-rich sequence is incapable of
maintaining unliganded 14-3-3 in the cytoplasm is incom-
patible with its proposed function as a true NES (Lopez-
Girona et al., 1999). Instead, our present study of FKHRL1
and previous studies on Cdc25 (Kumagai and Dunphy,
1999; Yang et al., 1999; Davezac et al., 2000) indicate that
export of the 14-3-3–bound complex involves NES se-
quences that are intrinsic to the ligands.
We reported previously an interaction between 14-3-3
and Crm1 within eukaryotic cell lysates that was disrupted
by a 14-3-3 binding peptide (Rittinger et al., 1999). At that
time, we interpreted this as evidence that the leucine-rich re-
gion within helix  I could interact with either ligands or
Crm1 but not both simultaneously. In light of our current
findings, the interaction that we observed between 14-3-3
and Crm1 was most likely mediated through the 14-3-3–
bound ligands, which were competed off by the 14-3-3
binding peptide. In agreement with this, we have been un-
able to show a direct interaction between 14-3-3 and Crm1
when both are expressed in Escherichia coli (unpublished
data).
Our findings are consistent with several different func-
tions for AKT and 14-3-3 in regulating the activity and
subcellular localization of FKHRL1. We have shown that
AKT-mediated phosphorylation of FKHRL1 at the 14-3-3
binding site within the nucleus results in accelerated nuclear
export of FKHRL1. This role for phosphorylation/14-3-3
binding in nuclear export is novel and complements recent
results from other investigators who reported, while our pa-
per was under revision, that AKT phosphorylation of the
FKHRL1 homologs AFX and FKHR can inhibit nuclear re-
import (Brownawell et al., 2001; Rena et al., 2001). In addi-
tion, Brownawell et al. (2001) proposed that phosphoryla-
tion at the 14-3-3 binding site did not affect nuclear export,
since a triple phosphorylation site mutant of AFX that could
not bind to 14-3-3 was able to shuttle between nuclei in het-
erokaryon fusion experiments. However, this study did not
examine the time dependence of the import or export pro-
cess, and our data in Fig. 8 indicates that phosphorylation at
the 14-3-3 binding site is critical for rapid nuclear export of
FKHRL1. Therefore, it is likely that AKT phosphorylation
of Forkhead family members affects both nuclear export and
import: phosphorylation/14-3-3 binding increases the rapid
export of FKHRL1 from the nucleus in a manner that re-
quires the intrinsic NES sequences on FKHRL1, whereas
phosphorylation near the NLS site may disrupt FKHRL1
subsequent nuclear reimport. Furthermore, Cahill et al.
Figure 8. Kinetics of FKHRL1 cytoplasmic relocalization after 
IGF-I stimulation shows a requirement for both 14-3-3 binding and 
NES sequences for rapid nuclear export and NLS for inhibition of 
nuclear reimport. CCL39 fibroblasts were transfected with a WT 
HA-tagged FKHRL1 construct or with various FKHRL1 mutant 
constructs. Cells were treated as in the legend to Fig. 6, and FKHRL1 
was detected by immunolocalization using an anti-HA antibody. 
The data presented correspond to the mean and variation of two 
experiments. Error bars are present for all time points, though in 
some cases they are obscured by the plot symbol. RRR, RRR → AAA 
mutant of FKHRL1; NESm, mutant of NES1 and NES2 of FKHRL1; 
TM, triple mutant of FKHRL1 (T32A/S253A/S315A).826 The Journal of Cell Biology | Volume 156, Number 5, 2002
(2001) showed that phosphorylation of the C.  elegans
FKHRL1 homologue daf-16 by AKT together with 14-3-3
binding directly inhibited its DNA binding ability. Thus,
AKT- and 14-3-3–mediated inhibition of FKHRL1 func-
tion is likely to involve multiple events, first by blocking
DNA binding and then by ensuring a complete sequestra-
tion of this transcription factor in the cytoplasm away from
their nuclear target genes.
We find that a K49E mutant of 14-3-3 is unable to bind
to ligands or be exported from the nucleus, despite its ability
to form heterodimers with endogenous WT 14-3-3 in vivo
and in vitro. This finding underscores the important role of
ligand binding by each monomer within the 14-3-3 dimer
for 14-3-3 function. A requirement for dimeric 14-3-3 has
also been demonstrated for both 14-3-3–mediated Raf acti-
vation (Tzivion et al., 1998) and for 14-3-3–mediated dis-
ruption of daf-16 DNA binding after AKT phosphorylation
(Cahill et al., 2001) using a mutant 14-3-3 in which the
dimerization interface was disrupted.
Our functional data shown in Fig. 8, examining FKHRL1
export as a function of time, shows an increase in nuclear ex-
port upon FKHRL1 phosphorylation and 14-3-3 binding,
which suggests that 14-3-3 may enhance the export process.
Exactly how 14-3-3 accomplishes this remains to be defined.
14-3-3 binding might facilitate the formation of productive
complexes between FKHRL1 and regulatory components of
the nuclear export machinery, perhaps through inducing
conformational changes in the 14-3-3–bound ligand. Recent
data from Brownawell et al. (2001) on AFX and our unpub-
lished observations on FKHRL1 suggest, however, that 14-
3-3 binding does not cause an increase in the bulk associa-
tion of these transcription factors with Crm1, though both
proteins are grossly overexpressed in these assays. It has not
been technically possible to measure the kinetics with which
the association occurs between the endogenous proteins
within cells. Alternatively, 14-3-3 binding could facilitate
the ability of FKHRL1–Crm1 complexes to bind to endoge-
nous Ran-GTP to trigger nuclear export. Another possibility
is that 14-3-3 binding protects phosphorylation sites from
the action of phosphatases and/or thereby permits additional
modifications of FKHRL1, which are themselves involved in
the export process.
We have focused this study specifically on one particular
14-3-3 ligand, FKHRL1, but studies on other 14-3-3 bind-
ing ligands such as HDAC4, -5, and -7 and Cdc25 are con-
sistent with the idea that cytoplasmic relocalization involves
both 14-3-3 proteins and ligand NES and NLS sequences
(Kumagai and Dunphy, 1999; Yang et al., 1999; Davezac et
al., 2000; Grozinger and Schreiber, 2000; Wang et al.,
2000; Kao et al., 2001). Furthermore, not all 14-3-3–bound
ligands are destined for cytoplasmic sequestration. For other
molecules, 14-3-3 binding may preferentially sequester them
within the nucleus as has been reported for the catalytic sub-
unit of human telomerase (Seimiya et al., 2000) and the
HOX11 homeobox transcription factor Tlx-2 (Tang et al.,
1998). Thus, it appears that the ligand, rather than 14-3-3,
dictates the resulting subcellular location (Muslin and Xing,
2000). In this manner, 14-3-3 functions as a type of “molec-
ular chauffeur” where the destination of the 14-3-3–bound
complex is determined by instructions contained within the
sequence and structure of the bound cargo rather than
through any intrinsic properties of 14-3-3. The ultimate fate
of such cargo is then determined by 14-3-3–mediated alter-
ations in the kinetics of dynamic nuclear-cytoplasmic trans-
port.
Materials and methods
Antibodies
Monoclonal antibodies against 14-3-3  were raised by immunizing DnJ
mice with purified GST–14-3-3  (Yaffe et al., 1997) and spleen fusions to
NS1 myeloma cells performed as described (Dalal et al., 1999). Clones
specifically recognizing 14-3-3  but not the other 14-3-3 isoforms were
identified by immunoprecipitation of in vitro–translated 14-3-3  and im-
munoblotting using GST fusion proteins of all mammalian 14-3-3 isotypes.
Additional details will be published elsewhere (unpublished data). An
anti–phospho-14-3-3 binding motif antibody was obtained from New En-
gland Biolabs. An antibody recognizing all 14-3-3 isotypes (K-19) were
purchased from Santa Cruz Biotechnology. Anti– -tubulin antibody
(DM1A) and anti-M2 antibody were purchased from Sigma-Aldrich. Anti-
HA antibody (12CA5) and anti–lamin B (Ab-1) antibody were obtained
from Roche-Boehringer Mannheim and Oncogene Research Products, re-
spectively. Anti-Xpress antibody and Cy3-conjugated anti–mouse IgG
secondary antibody were obtained from Invitrogen and Jackson Immu-
noResearch Laboratories, respectively. The anti-phosphoThr32 FKHRL1
antibody has been described previously (Brunet et al., 1999).
Plasmids
Plasmids encoding GST–14-3-3 , GST–14-3-3  K49E, HA-FKHRL1 WT,
and FKHRL1 T32A/S253A/S315A have been described previously (Brunet
et al., 1999; Rittinger et al., 1999). GST–14-3-3  ([1–214];  C) and GST–
14-3-3  ([1–232];  T) were generated by PCR amplification and cDNA
cloning into pGEX4T. cDNAs of 14-3-3  WT and 14-3-3  K49E were sub-
cloned into mammalian expression vector pcDNA3.1/His C (Invitrogen) to
express Xpress epitope-tagged 14-3-3. The vector encoding the M2-tagged
form of 14-3-3  subcloned in the pcDNAneo3 expression vector was pro-
vided by Dr. Haian Fu (Emory University School of Medicine, Atlanta,
GA). Sequential point mutations of individual leucine and isoleucine resi-
dues to alanines in helix  I of GST–14-3-3  were generated using specific
oligonucleotides and the Quickchange site-directed mutagenesis kit (Strat-
agene). A mutant of FKHRL1 NES1 (amino acids 369–378) and NES2
(amino acids 386–396) was obtained as follows: first, a mutant of FKHRL1
NES2 (LMDDAADNATA) was generated using the following set of prim-
ers: forward, 5 -AAAGCTGCAGATAACGCCACGGCCCCGCCATCCCAG-
CCATCGC-3   and  reverse, 5 -AAAGGCCGTGGCGTTATCTGCAGCG-
TCGTCCATGAGGTTTTCAG-3 . The PCR fragment was subcloned into
the Acc I sites of HA-FKHRL1 in the pECE vector. FKHRL1 NES2 mutant
was then used as a template to generate FKHRL1 NES1-NES2 mutant
(LTDMAGTANANDGATENLMDDAADNATA) using the following set of
primers: forward, 5 -AAAGCGAATGCGAATGATGGGGCGACTGAAAAC-
CTCATGGACGAC-3   and reverse, 5 -AAACGCCCCATCATTCGCATT-
CGCGGTGCCTGCCATATCAGTCAGC-3 . The triple point mutants of
FKHRL1 NLS sequences were produced with the Quickchange site-
directed mutagenesis kit (Stratagene) using the following primers: RRR →
AAA forward, 5 -GGGAAGAGCGGAAAAGCCCCCGCGGCGGCGG-
CTGTCTCCATGGACAATAGC-3   and  RRR  →  AAA reverse, 5 -GCTAT-
TGTCCATGGAGACAGCCGCCGCCGCGGGGGCTTTTCCGCTCTTCCC-3 
and  KKK  →  AAA forward, 5 -GAGCCGTGGCCGCGCAGCCGCGGCG-
GCGGCAGCCCTGCAGACAGCCCCCG-3   and  KKK  →  AAA reverse,
5 -CGGGGGCTGTCTGCAGGGCTGCCGCCGCCGCGGCTGCGCGGCC-
ACGGCTC-3 .
Cell lines and transfection
The 293T human epithelial kidney cell line, human osteosarcoma U2OS
cell line, and Chinese hamster lung fibroblast cell line CCL39 were cul-
tured in DME supplemented with 10% FBS, and NIH3T3 cells were
maintained in DME with 10% calf serum. LMB was used at final con-
centration of 20 ng/ml. To establish stable cell lines expressing 14-3-3
proteins, U2OS cells were transfected with pcDNA3.1/His-14-3-3  or
pcDNA3.1/His-14-3-3  (K49E) using Superfect (QIAGEN) and trans-
fected cells selected in media containing 400  g/ml G418 (GIBCO
BRL). After 2 wk, resistant colonies were tested for expression of
epitope-tagged 14-3-3 by immunoblotting and used to propagate stable
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Cellular fractionation, immunoblotting, and 14-3-3
binding assays
U2OS cells were suspended in buffer A (10 mM Hepes, pH 7.9, 10 mM
KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.15% NP-40, 1 mg/ml
each of AEBSF, aprotinin, leupeptin, and pepstatin), swollen for 10 min on
ice, and centrifuged at 12,000 g for 30 s. Supernatant was collected as a
cytoplasmic extract. The pellet was washed, resuspend in buffer B (20 mM
Hepes, pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT,
0.5% NP-40, 4  g/ml each of AEBSF, aprotinin, leupeptin, and pepstatin),
and rocked for 15 min at 4 C. The supernatant after centrifugation was
used as nuclear extract. Equal amounts of proteins from cytosol and nu-
clear extract were subjected to immunoblotting as described (Kanai et al.,
2000). To investigate the distribution of 14-3-3 ligands, cells were meta-
bolically labeled in the presence of [
35S]methionine for 8 h and then sepa-
rated into nuclear or cytoplasmic fractions as above. Samples (240  g total
protein containing equal amounts of radioactivity) were adjusted to the
same final buffer composition and pulled down with beads containing 150
 g of GST–14-3-3  or GST as described (Rittinger et al., 1999). Proteins
binding to the beads were eluted, separated by SDS-PAGE, and analyzed
by autoradiography. To analyze the interaction between FKHRL1 and 14-
3-3, 293T cells transfected with HA-FKHRL1 constructs and M2–14-3-3 
were lysed and subjected to immunoprecipitation and immunoblotting as
described previously (Brunet et al., 1999).
Immunofluorescence microscopy
Immunofluorescent microscopy was done as described (Brunet et al.,
1999; Kanai et al., 2000). U2OS cells grown on glass coverslips were fixed
with 3% formaldehyde, permeabilized with 0.2% Triton X-100, and
stained with an anti–14-3-3 antibody (K-19) or an anti–14-3-3  mono-
clonal antibody and Cy3-conjugated secondary antibodies. Cells were
counterstained with 1  g/ml DAPI (Sigma-Aldrich) to visualize the nu-
cleus. The anti-Xpress antibody was used to stain 14-3-3–expressing stable
cell lines. For immunolocalization studies of FKHRL1, CCL39 fibroblasts
on glass coverslips in 12-well dishes were transfected with 4  g of the in-
dicated plasmids using calcium phosphate. After 24 h, the cells were fixed
in 4% formaldehyde/2% sucrose, permeabilized with 0.1% Triton X-100,
and stained with anti-HA antibody, anti-phosphoT32 antibody, and Cy3-
or Cy2-conjugated anti–mouse IgG secondary antibody and Cy3-conju-
gated anti–rabbit IgG secondary antibody. For quantification experiments,
150–300 cells were scored according to whether the protein of interest
was higher in the nucleus, evenly distributed between nucleus and cyto-
plasm, or higher in cytoplasm. Microscopic images were acquired using
Nikon Diaphot 300 microscope mounted with a Photometrics SenSys CCD
camera and processed using Vaytek Imaging Software.
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